Tag: Clinical Study

Jardiance Failed to Meet Primary Endpoint in Clinical Study

Jardiance, a type 2 diabetes drug developed by Boehringer Ingelheim and Eli Lilly and Company, failed to meet the primary endpoint of two late-stage exercise ability trials in chronic heart failure. ...

Allergan Presented Positive Data from Clinical Studies of Investigational Abicipar

allergan
Allergan plc., a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners, a clinical-stage biopharmaceutical company developing a new class of d...

Novartis Announce Positive Results of Cosentyx® Study

clinical-trial
Novartis, a leader in rheumatology and immuno-dermatology, announced additional positive data from the PREVENT trial, evaluating the efficacy and safety of Cosentyx® (secukinumab) in patients with non...

GSK Announced Results from PRIMA Study of Zejula

gsk
GlaxoSmithKline plc announced results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomised, double-blind, placebo-controlled study of Zejula (niraparib) as a maintenance therapy in women with firs...

Jazz Pharma Announced Positive Data from Phase 3 Study of Investigational Medicine JZP-258

Jazz Pharmaceuticals plc announced that positive data from the Phase 3 study of its investigational medicine, JZP-258, for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adults w...

Sertraline ‘Unlikely’ to Treat Depressive Symptoms, Study Shows

A new study has found that sertraline (sold as Zoloft among other names), despite being marketed as an antidepressant, may be ‘unlikely’ to treat depressive symptoms within six weeks, but does show im...

IAOCR to Launch New Safety Campaign

The International Academy of Clinical Research (IAOCR) has launched a new patient safety campaign, just in time for the first ever World Patient Safety Day. The campaign calls on the industry to pr...

Eisai and Biogen Decided to Discontinue Clinical Studies on Oral BACE Inhibitor

Eisai Co., Ltd. and Biogen Inc. announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbe...

Spravato Reduce Symptoms in 24 Hours, Study Shows

The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive results from two pivotal Phase 3 clinical studies to evaluate the efficacy and safety of esketamine nasal spray in addi...

Amgen and Allergan Announced Positive Results from Clinical Study of Rituxan®

research
Amgen and Allergan plc. announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to...

Janssen Announced Positive Top-Line Results from Study of Cabotegravir

hiv
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced positive top-line results from the Phase 3 ATLAS-2M study of the investigational, long-acting two-drug injectable regimen o...

ViiV Healthcare Announced Positive Results from Clinical Study of Combo for HIV Treatment

viiv healthcare
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced positive headline results from its global phase III ATLAS-2M ...

Eli Lilly Announced Superiority of Taltz® (ixekizumab) versus TREMFYA® after Phase 4 IXORA-R Study

clinical trials
Eli Lilly and Company announced Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versu...

Digital Devices May Help Identify Mild Alzheimer’s Disease Dementia, Lilly Study Showed

lilly
Initial results from a feasibility study conducted by Eli Lilly and Company, Evidation Health, and Apple Inc. showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combin...

Boehringer Ingelheim Updated Real-World Data on Gilotrif

Boehringer Ingelheim announced updated, interim analysis results from the GioTag study, showing that initiating treatment with afatinib followed by osimertinib provided an overall survival (OS) of alm...

Pfizer Announced Negative Phase 3 Results for Rivipansel

pfizer
Pfizer announced that the Phase 3 Rivipansel (GMI1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The obj...